66 results about "Anti microbial peptide" patented technology

The present disclosure is directed to an engineered lysin comprising: (a) a Gram-negative base lysin; and (b) one or more antimicrobial peptide (AMP) and / or cell penetrating peptide (CPP), and optionally an outer membrane binding motif and at least one linker, or an active fragment thereof, or a variant thereof having at least 80% sequence identity. Also disclosed herein are methods of treating a bacterial infection caused by at least one Gram-negative bacteria and methods of killing at least one Gram-negative bacteria, comprising administering the engineered lysin disclosed herein.

The present disclosure is directed to an engineered lysin comprising: (a) a Gram-negative base lysin; and (b) one or more antimicrobial peptide (AMP) and / or cell penetrating peptide (CPP), and optionally an outer membrane binding motif and at least one linker, or an active fragment thereof, or a variant thereof having at least 80% sequence identity. Also disclosed herein are methods of treating a bacterial infection caused by at least one Gram-negative bacteria and methods of killing at least one Gram-negative bacteria, comprising administering the engineered lysin disclosed herein.

Disclosed herein are methods of diagnosing, selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD, based on presence of antimicrobial peptides (AMPs) at levels that differ from those in control individuals.

Provided are an antimicrobial peptide or a pharmaceutical composition thereof, and the use thereof. The antimicrobial peptide is a new efficient antimicrobial peptide, has the characteristics of small molecular weight, broad antibacterial spectrum, high efficiency, no cytotoxicity, no hemolytic property, high stability, low susceptibility to developing drug resistance, etc., and can kill microorganisms including clinically common drug-resistant strains, bacteria, and fungi. Moreover, the antimicrobial peptide has the advantages of simple structure, easy large-scale synthesis and low cost, and the antimicrobial peptide is expected to replace antibiotics to become a safe, green and efficient ideal antimicrobial agent, and has very wide application prospects in the fields of the preparation of antimicrobial drugs, antimicrobial preparations, antimicrobial products, etc.

Provided in this disclosure are pharmaceutical formulations comprising antimicrobial peptides with enhanced stability. Further provided herein are methods of treating or preventing an infection comprising administering pharmaceutical formulations comprising antimicrobial peptides when administered to a subject.

The invention belongs to the technical field of phospholipid membrane monolithic columns, and particularly relates to a preparation method and application of a bionic phospholipid membrane monolithic column for screening and separating antimicrobial peptides. The bionic phospholipid membrane monolithic column is prepared from phospholipid monomers or mixed phospholipids, and is directly prepared in a quartz capillary through an in-situ polymerization reaction, so that the monolithic column has richer phospholipid types and a more complex phospholipid membrane structure, a biological membrane environment can be more accurately simulated, and the separation efficiency and selectivity are improved; the obtained mixed phospholipid membrane monolithic column is relatively good in polymerization condition, is tightly combined with a capillary wall, is excellent in structural performance, can realize separation of alkyl benzophenone compounds, has non-specific adsorption resistance, can also be used for separation, purification and screening of antibacterial peptides, and has wide application prospects. The method has important significance, and solves the problems of low efficiency, high cost, activity loss and the like existing in the conventional antibacterial peptide screening and purifying method.

The invention relates to an antimicrobial peptide consisting of the amino acid sequence: RX1WILX2WLRTWX3X4 wherein X1, X2, X3 and X4 are independently selected from K and R, and wherein each amino acid is independently in the L or D configuration, or a salt or solvate thereof. The use of said antimicrobial peptide in the treatment of an infection caused by Gram negative bacteria, Gram positive bacteria, fungi, and / or yeasts, as well as the use of said peptide as an antimicrobial agent for the prevention of contamination of an article or a living tissue by and / or for the decontamination of an article or a living tissue from Gram negative bacteria, Gram positive bacteria, fungi, and / or yeasts are further aspects of the invention.

The present invention is directed to peptidomimetics having antibacterial activity, especially against Gram-negative bacteria. The peptidomimetics of the invention are compounds of the general formula (I), P1-P2-P3-P4-P5-P6-P7-P8-P9-P10-P11-P12-P13-P14-P15-P16 (I) and salts thereof, in particular pharmaceutically acceptable salts thereof, as described in the description and in the claims. The invention is also directed to therapeutic uses of the peptidomimetics for the treatment or prevention of bacterial infections and diseases related to bacterial infections and to non-therapeutic uses of the peptidomimetics for preserving or disinfecting foodstuffs, cosmetics, medicaments or other nutrient-containing materials.

Disclosed herein are novel antimicrobial peptides with useful, improved, or superior properties such as antimicrobial activity, desirable levels of hemolytic activity, and therapeutic index against a broad range of microorganisms including gram-negative and gram-positive bacteria and other organisms having a cellular or structural component of a lipid bilayer membrane. Also provided are methods of making and using such peptides to control microbial growth and in pharmaceutical compositions for the treatment of infections caused by such microorganisms.

The present invention relates to topical formulations comprising a combination of antimicrobial peptides (AMP), in particular synthetic cyclic peptide compounds based on thiazolidine and # imgabs0 # oxazolidine components, and a skin soothing substance, such as menthoxypropanediol, a substance that enhances the skin barrier, such as omega-6 fatty acids, and / or a flavonoid, such as licochalcone, for example licochalcone, for example licochalcone, for example licochalcone, for example licochalcone, for example licochalcone, for example licochalcone, for example licochalcone, for example licochalcone, for example licochalcone, for example licochalcone, for example licochalcone. In particular, the present invention relates to compounds that synergistically and selectively fight against pathogenic bacteria, such as Staphylococcus aureus (S. aureus) and Propionibacterium acnes (C. acnes), but not fight against skin symbiotic bacteria, such as Staphylococcus epidermidis (S. epidermidis). The formulations can be advantageously used in the treatment of acne or atopic dermatitis, as well as in the care of skin that has been impaired by acne or atopic dermatitis.

A stapled antimicrobial peptide having the amino acid sequence FFRKSKEK-S5-GKE-S5-KRIV (SEQ ID NO: 1) and its use as an antimicrobial and anticancer agent are provided.

The present invention relates to antimicrobial peptides derived from Romo1 protein, and specifically, a plurality of peptides are provided, each of which has an amino acid sequence of the α-helix 2 region of Romo1 protein, and its antimicrobial activity against Gram-positive, Gram-negative and multidrug-resistant bacteria is determined; and an antimicrobial composition comprising the peptide is provided. The Romo1-derived peptides and variants thereof of the present invention are superior to existing antibiotics and antibiotic peptides in terms of antibiotic ability against various types of bacteria and multidrug-resistant bacteria, and in particular, have antimicrobial activity against various bacteria in blood vessels, and therefore, are new antibiotics that can be provided as a substance for preventing or treating a wide range of bacterial infectious diseases. Therefore, the composition comprising the antimicrobial peptides of the present invention is expected to be used in a variety of fields for the purpose of preventing or treating infectious diseases, for example, as drugs, quasi-drugs, food and feed additives, and agricultural and cosmetic additives.

In some embodiments herein, methods and compositions for preparing bacteriocins are described. In some embodiments, the propolypeptide can be produced by a microbial cell comprising a nucleic acid encoding the propolypeptide, which comprises a bacteriocin separated by a cleavage site and cis of a desired ratio. In some embodiments, microfluidic devices and methods for preparing a specified mixture of antimicrobial peptides and / or bacteriocins are described.

Antimicrobial peptides of general formula X0X1X2C X3X4X5CX6X7X8X9CYX10X11CX12X13 are provided. Also provided are certain formulations containing these peptides and methods of using these peptides for treating skin infections in an animal in need thereof.

Embodiments herein relate to methods, systems and kits for engineering antimicrobial peptides such as bacteriocins, for example to have a desired range of activity in a desired range of culture conditions. The antimicrobial peptides may be engineered to have a particular activity for a particular culture, environmental conditions or a range of conditions. Some embodiments include screening an antimicrobial peptides or several candidate antimicrobial peptides for a desired activity. Some embodiments include an iterative process for engineering antimicrobial peptides such as bacteriocins. In some embodiments, the process is performed by automated machine learning.

An antimicrobial peptide having an amino acid sequence selected from SEQ ID NOs: 2-12 is provided. The antimicrobial peptide has antimicrobial activity against Gram-negative bacteria, Campylobacter jejuni, Escherichia coli, Salmonella enterica subsp. enterica serovar typhimurium, Salmonella enterica subsp. enterica serovar choleraesuis, Klebsiella pneumonica, and / or Enterobacter cloacae. A composition, pharmaceutical composition, food additive, cosmetic composition, or hygine product having an antimicrobial peptide including an amino acid sequence selected from SEQ ID NOs: 2-12 is also provided. A method of treating an infectious disease caused by bacteria including a step of administering a pharmaceutical composition having the antimicrobial peptide as an active ingredient is also provided.

The invention belongs to the technical field of biological medicines, and particularly relates to application of an anti-HPV16 antimicrobial peptide in preparation of an antiviral medicine. The amino acid sequence of the antimicrobial peptide Perceptide-TJ-2 is as shown in SEQ ID NO. 1, and the antimicrobial peptide Perceptide-TJ-2 is an amino acid sequence shown in SEQ ID NO. The invention evaluates the antiviral activity of the antimicrobial peptide Perceptide-TJ-2 on HPV16 in vitro, the antimicrobial peptide Perceptide-TJ-2 can effectively inhibit the infection of HPV16 on cells at a lower concentration, the drug selection index reaches 64.64, and the antimicrobial peptide Perceptide-TJ-2 has a certain application prospect and provides a new possibility for the research and development of anti-HPV treatment drugs.

A method of increasing antimicrobial peptide concentration on the skin is provided. The method includes cleaning skin with at least one of a cleanser and a sanitizer and applying a topical composition to the skin. The topical composition is comprised of one or more polypeptides and natural extracts that increase the concentration of antimicrobial peptides.

An antimicrobial peptide for maintaining the health of scalp microbiome, including one of the following polypeptides (1)-(7): (1) a polypeptide including an amino acid sequence shown in SEQ ID NO: 1, or a polypeptide consisting of amino acid residues of SEQ ID NO: 1; (2) a polypeptide including an amino acid sequence shown in SEQ ID NO: 2, or a polypeptide consisting of amino acid residues of SEQ ID NO: 2; (3) a polypeptide resulting from substitution, deletion, and / or addition of one or more amino acid residues of the polypeptide in (1) or (2); (4) a polypeptide obtained by modifying a N-terminus and / or a C-terminus of the polypeptide in (1) or (2); and (5) a polypeptide having at least 85%, 90%, 95%, 98%, or 99% sequence identity to the amino acid sequence of the polypeptide in (1) or (2). The antimicrobial peptide exhibits excellent safety for treating scalp conditions.

The present invention provides antimicrobial peptide compounds, pharmaceutical compositions and methods of their use for inhibiting the growth of microorganisms. The present invention also relates to a method for inhibiting the total drug resistance of Acinetobacter baumannii, and a method for inhibiting the total drug resistance of Acinetobacter baumannii by administering the peptide compound to a subject. Provided is a method for the inhibition of fully drug resistant Acinetobacter baumannii using a synergistic combination of the peptide compound acetyl-AS-aib-LRKL-aib-KRLL-amide (SEQ ID NO: 1) and polymyxin B. The invention also provides a method for the inhibition of fully drug resistant Acinetobacter baumannii. In other methods, a peptide compound is provided for the inhibition of Porphyromonas gingivalis (P.gingivalis), which is the key bacterium of the most six most common infectious periodontal disease in the world.

Disclosed herein are methods and compositions for use in controlling citrus greening, citrus canker, or fire blight, wherein the compositions comprise one or more antimicrobial peptides, or one or more polynucleotides encoding for the one or more antimicrobial peptides.

Disclosed herein are methods and compositions for use in controlling citrus greening, citrus canker, or fire blight, wherein the compositions comprise one or more antimicrobial peptides, or one or more polynucleotides encoding for the one or more antimicrobial peptides.

One aspect of the present disclosure relates to the use of vitrified active agents such as growth factors and / or one or more antimicrobial peptides (AMPs), or other desired active agent, for wound healing as a component of a wound dressing whereby the active agents are vitrified onto one or more polymeric materials, and their release rate regulated by the presence of one or more biodegradable polymeric materials.

The invention relates to a compound atomized liquid for pet respiratory mucosa and a preparation method thereof. Each 100 mL of the compound atomized liquid is prepared from 0.15 to 0.20 g of a liquorice root extract, 0.18 to 0.25 g of L-lysine hydrochloride, 0.20 to 0.25 g of chitosan oligosaccharide, 0.25 to 0.35 g of yeast-beta-glucan, 0.008 to 0.015 g of EDTA-2Na (Ethylene Diamine Tetraacetic Acid), 0.4 to 0.6 g of trehalose, 0.65 to 0.75 g of sodium chloride, 0.5 to 1.0 mg of micromolecular antimicrobial peptide and the balance of citric acid / phosphate buffer solution. Wherein the molecular weight of the chitosan oligosaccharide is less than or equal to 2000Da; the pH value of the compound atomized liquid is 6.0-7.0; and the osmotic pressure of the compound atomized liquid is 280-320 mOsm / kg. By compounding the natural anti-inflammatory component, the immunopotentiator, the mucosa protective agent and the micromolecular antimicrobial peptide, synergistic treatment is realized, and side effects are reduced.

Antimicrobial modified defensins or defensin-like peptides, modified C-terminal fragments of defensins or defensin-like peptides, and nucleic acids encoding the same are disclosed. Also disclosed are compositions comprising the defensin variant peptides and methods of using the same to control microbial infections and feed and food contamination in plant and vertebrate subjects.

The present invention provides novel kinocidin peptides comprising a C-terminal portion of a kinocidin, wherein the C-terminal portion encompasses an α-helical secondary structure and further displays antimicrobial activity. The kinocidin peptides of the invention are derived from and correspond to a C-terminal portion of a kinocidin that includes a γκO core and that can be a CXC, CC, or C class chemokine. Structural, physicochemical and functional properties of this novel class of antimicrobial peptides and amino acid sequences of particular kinocidin peptides are also disclosed. The invention also provides related antimicrobial methods.

One aspect of the present disclosure relates to the use of vitrified active agents such as growth factors and / or one or more antimicrobial peptides (AMPs), or other desired active agent, for wound healing as a component of a wound dressing whereby the active agents are vitrified onto one or more polymeric materials, and their release rate regulated by the presence of one or more biodegradable polymeric materials.

The present invention relates to methods for maturing the mucosal defense and rebalancing the immune system preventing a cytokine storm; treatment or prevention of neonatal sepsis, necrotizing enterocolitis, acute and prolonged diarrhea, short bowel syndrome, respiratory illness, respiratory infection, respiratory failure, impaired neurodevelopment and extra uterine growth restriction, the method comprising oral and / or intrapulmonary and / or subcutaneous administration of at least one antimicrobial peptide selected from the group consisting of a-defensins, β-defensins, cathelicidins, lactoferrins / lactoferricins and lysozymes and / or GLP-2 or GLP-2 analogs in a preterm infant or a mother about to give birth to a preterm infant.

The present disclosure relates to a group of Antimicrobial peptides (referred to as “LysECD7 variants” or “LysECD7 variant proteins”) that are based on the wild-type enzyme LysECD7 but with specific amino acid substitutions, poly nucleotides and vectors encoding the same, peptide fragments thereof, cells or spores expressing the poly nucleotide or vector, and methods of using and making the same. In addition, the present disclosure relates to spore-associated or microbe-associated LysECD7 variants. The association of LysECD7 variants with spores or microbes can include surface display by covalent or noncovalent association or by mixing. The present disclosure is further directed to fragments or subsequences of LysECD7 variant nucleic acids comprising hybridizable portions of the LysECD7 variant sequence which have use. e.g. in nucleic acid-based assays.

This invention discloses an antiviral disinfectant wipe based on the synergistic effect of biocatalytic sterilization and physical membrane disruption, belonging to the field of disinfectant wipe technology. The disinfectant wipe contains the following raw materials in parts by weight: 85-95 parts spunlace nonwoven fabric, 0.08-0.15 parts modified antimicrobial peptides, 1.5-3 parts modified chitosan, 820-930 parts deionized water, 22-28 parts propylene glycol, 18-22 parts glycerin, 6-9 parts sodium cocoyl glycinate, 0.8-1.2 parts citric acid, 0.8-1.0 parts phenoxyethanol, and 4-7 parts aloe vera extract. This antiviral disinfectant wipe focuses on the synergistic effect of physical membrane disruption and catalytic sterilization. The raw material ratio is scientific, containing highly effective components such as modified antimicrobial peptides and modified chitosan, resulting in excellent sterilization and antiviral effects. The preparation process is standardized, with strict pretreatment of the nonwoven fabric, uniform solution dispersion, and controllable product liquid content. The addition of aloe vera extract makes it mild and non-irritating, allowing for flexible storage and high practicality.